nilvadipine and Day Blindness studies

nilvadipine and Day Blindness

nilvadipine has been researched along with Day Blindness in 1 studies

Research Excerpts

Excerpt	Relevance	Reference
"To assess the effects of nilvadipine on the progression of central visual field defect in retinitis pigmentosa (RP)."	9.15	Effect of nilvadipine on central visual field in retinitis pigmentosa: a 30-month clinical trial. ( Ito, T; Metoki, T; Miyagawa, Y; Nakazawa, M; Ohguro, H; Takeuchi, K, 2011)
"To assess the effects of nilvadipine on the progression of central visual field defect in retinitis pigmentosa (RP)."	5.15	Effect of nilvadipine on central visual field in retinitis pigmentosa: a 30-month clinical trial. ( Ito, T; Metoki, T; Miyagawa, Y; Nakazawa, M; Ohguro, H; Takeuchi, K, 2011)

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Timeframe

Studies, this research(%)

All Research%

pre-1990

0 (0.00)

18.7374

1990's

0 (0.00)

18.2507

2000's

0 (0.00)

29.6817

2010's

1 (100.00)

24.3611

2020's

0 (0.00)

2.80

Authors

Authors	Studies
Nakazawa, M	1
Ohguro, H	1
Takeuchi, K	1
Miyagawa, Y	1
Ito, T	1
Metoki, T	1

Studies

Nakazawa, M

Ohguro, H

Takeuchi, K

Miyagawa, Y

Ito, T

Metoki, T

Trials

1 trial available for nilvadipine and Day Blindness

Article	Year
Effect of nilvadipine on central visual field in retinitis pigmentosa: a 30-month clinical trial. Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde, 2011, Volume: 225, Issue:2 Topics: Administration, Oral; Adult; Aged; Calcium Channel Blockers; Disease Progression; Female; Follow-Up	2011

Article

Year

Effect of nilvadipine on central visual field in retinitis pigmentosa: a 30-month clinical trial.

Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde, 2011, Volume: 225, Issue:2

Topics: Administration, Oral; Adult; Aged; Calcium Channel Blockers; Disease Progression; Female; Follow-Up

2011